WebOct 1, 2024 · The precision cellular therapy, Orca-T, demonstrated improvement in 1-year graft-versus-host disease (GVHD)-free relapse-free survival (GRFS) compared with standard transplant following myeloablative conditioning (MAC) for hematological malignancies, according to findings from 2 studies. 1 The findings were presented by Samer Srour, … WebFeb 11, 2024 · Everett H. Meyer, MD, PhD. Data presented during the 2024 Transplantation and Cellular Therapy Meeting showed that treatment with Orca-T, a first-generation …
Abstract - American Society of Hematology
WebMar 31, 2024 · This is a first in children prospective study of allogeneic hematopoietic cell transplant using a centrally manufactured engineered donor graft (Orca-Q). The study will assess safety and efficacy of Orca-Q in pediatric patients with hematologic malignancies. WebGvHD, graft-versus-host disease; PTCy, post-transplant cyclophosphamide. Orca-Q is an investigational, precision-engineered cell therapy comprised of stem and immune cells isolated from a suitable donor, that is hypothesized to reduce … czech republic and china
Orca Bio Receives Regenerative Medicine Advanced Therapy
WebFeb 9, 2024 · Patients with myelofibrosis who underwent myeloablative allogeneic stem cell transplantation followed by Orca-T treatment experienced improved outcomes, according to a subgroup analysis of a single-center phase 2 trial (NCT04013685) and a multicenter phase 1b trial (NCT01660607), which were presented at the 63rd Annual American Society of … WebFeb 9, 2024 · Orca-T Graft Shows Efficacy, Tolerability in Post-ASCT Myelofibrosis. Feb 9, 2024. Gina Mauro. An expert with Oregon Health & Science University discusses whether … WebAug 2, 2024 · Orca Bio Announces the Precision-T Phase 3 Study is Open and Enrolling Patients at Transplant Centers Across the U.S. August 2, 2024, 9:00 AM · 4 min read – The pivotal Precision-T Study is... czech republic and nato